Literature DB >> 8973833

Block of the endplate acetylcholine receptor channel by the sympathomimetic agents ephedrine, pseudoephedrine, and albuterol.

M Milone1, A G Engel.   

Abstract

Recent observations suggest that some patients with congenital myasthenic syndromes respond favorably to ephedrine, pseudoephedrine, or albuterol. Conventional microelectrode studies, however, provide no clear explanation for a beneficial effect of ephedrine in endplate diseases. To gain further insight into how these drugs affect neuromuscular transmission, we investigated their effects on the kinetic properties of the acetylcholine (ACh) receptor. Single channel currents were recorded from rat lumbrical muscles endplates using low concentrations of ACh and 2.5-100 microM of drugs. Between 10-100 microM, each drug progressively increased the rate of channel closure in a concentration dependent manner, consistent with an open-channel block. Albuterol acted as a sequential fast-acting channel blocker, increasing the mean burst duration in a concentration dependent manner without altering the total open time per burst or the duration of intraburst blockages. Increasing concentrations of ephedrine and pseudoephedrine also increased the number of intraburst closures but decreased the total open time per burst. None of the drugs altered single channel conductance. The channel blocking effects of ephedrine and pseudoephedrine might reduce the synaptic overactivity that occurs in the slow-channel myasthenic syndromes or in endplate ACh esterase deficiency, but these effects occur at concentrations not attainable in clinical practice.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8973833     DOI: 10.1016/s0006-8993(96)00894-3

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  14 in total

1.  Ephedrine treatment in congenital myasthenic syndrome due to mutations in DOK7.

Authors:  D Lashley; J Palace; S Jayawant; S Robb; D Beeson
Journal:  Neurology       Date:  2010-05-11       Impact factor: 9.910

2.  Beneficial effects of albuterol in congenital endplate acetylcholinesterase deficiency and Dok-7 myasthenia.

Authors:  Teerin Liewluck; Duygu Selcen; Andrew G Engel
Journal:  Muscle Nerve       Date:  2011-09-23       Impact factor: 3.217

3.  Salbutamol modifies the neuromuscular junction in a mouse model of ColQ myasthenic syndrome.

Authors:  Grace M McMacken; Sally Spendiff; Roger G Whittaker; Emily O'Connor; Rachel M Howarth; Veronika Boczonadi; Rita Horvath; Clarke R Slater; Hanns Lochmüller
Journal:  Hum Mol Genet       Date:  2019-07-15       Impact factor: 6.150

4.  The potential use of ephedrine in Lambert-Eaton myasthenic syndrome : clinical and electrophysiological evaluation.

Authors:  Carlo Cereda; Thierry Kuntzer
Journal:  J Neurol       Date:  2008-06-13       Impact factor: 4.849

Review 5.  The rush to adrenaline: drugs in sport acting on the beta-adrenergic system.

Authors:  E Davis; R Loiacono; R J Summers
Journal:  Br J Pharmacol       Date:  2008-06       Impact factor: 8.739

Review 6.  Nicotinic acetylcholine receptors at the single-channel level.

Authors:  Cecilia Bouzat; Steven M Sine
Journal:  Br J Pharmacol       Date:  2017-04-08       Impact factor: 8.739

7.  Beneficial effect of albuterol in congenital myasthenic syndrome with epsilon-subunit mutations.

Authors:  Menachem Sadeh; Xin-Ming Shen; Andrew G Engel
Journal:  Muscle Nerve       Date:  2011-06-30       Impact factor: 3.217

Review 8.  Ephedrine for myasthenia gravis, neonatal myasthenia and the congenital myasthenic syndromes.

Authors:  Charlotte Vrinten; Angeli M van der Zwaag; Stephanie S Weinreich; Rob J P M Scholten; Jan J G M Verschuuren
Journal:  Cochrane Database Syst Rev       Date:  2014-12-17

9.  Activation and block of mouse muscle-type nicotinic receptors by tetraethylammonium.

Authors:  Gustav Akk; Joe Henry Steinbach
Journal:  J Physiol       Date:  2003-06-24       Impact factor: 5.182

Review 10.  Adrenoceptors Modulate Cholinergic Synaptic Transmission at the Neuromuscular Junction.

Authors:  Ellya Bukharaeva; Venera Khuzakhmetova; Svetlana Dmitrieva; Andrei Tsentsevitsky
Journal:  Int J Mol Sci       Date:  2021-04-28       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.